Author Affiliations: Endocrine Unit, Department of Medical Sciences (Drs Salvi, Vannucchi, Covelli, and Beck-Peccoz) and Departments of Ophthalmology (Drs Currò and Ratiglia), Internal Medicine (Dr Bonara), and Otolaryngology (Drs Guastella and Pignataro), University of Milan and Fondazione Cà Granda, IRCCS, and Department of Pathology, Azienda Ospedaliera San Paolo and Azienda Ospedaliera Istituto Ortopedico Gaetano Pini (Dr Rossi), Milan, Laboratory of Cellular and Gene Therapy, Ospedali Riuniti di Bergamo, Bergamo (Drs Introna and Golay), and Division of Internal Medicine, Ospedale di Fidenza, Fidenza (Dr Dazzi), Italy.
Rituximab has been used in the treatment of several autoimmune diseases.1 Preliminary studies from our laboratory,2 recently confirmed,3 have shown that 2 cycles of 1000 mg of rituximab induced peripheral CD20+ cell depletion and significant clinical improvement of active Graves orbitopathy (GO). We report an unexpectedly rapid therapeutic effect of 100 mg of rituximab observed in 3 patients as early as 1 to 7 days after therapy, with persistent inactivation of inflammation and total depletion of CD20+ and CD19+ B cells. Immunohistochemistry of orbital tissues from patients treated with rituximab has shown early recruitment of type 2 macrophages, which may be involved in rituximab-induced phagocytosis of B-cell targets in orbital tissues.
Patients with GO underwent rituximab infusion after premedication with acetaminophen, chlorpheniramine maleate, and 100 mg of hydrocortisone sodium succinate. Peripheral cell subpopulation analysis was performed at baseline, at the time of the acute reaction (60 minutes), and weekly thereafter by flow cytometry (Figure 1C). Orbital tissues after treatment with 100 mg of rituximab, treatment with steroids, and no treatment of GO were studied by immunohistochemistry (Figure 2A). Lymphocytic infiltration was graded 1+, 2+, and 3+ if there were fewer than 10, more than 10, and more than 30 immunoreactive cells per high-power field (magnification ×400), respectively.
Figure 1. Effects of rituximab treatment. A, Decrease of the clinical activity score (CAS) in 2 patients with an infusion-related reaction after a single 100-mg dose of rituximab compared with the mean CAS decrease observed in 10 patients with active Graves orbitopathy treated with the standard dose of 2 cycles of 1000 mg of rituximab.2 B, Photographs of the patients with active Graves orbitopathy before and after treatment with rituximab. C, Time course of the depletion of CD20+ cells in the same patients after receiving 100 mg of rituximab compared with depletion observed in 10 patients with active Graves orbitopathy treated with 2 cycles of 1000 mg of rituximab.2
Figure 2. Degree of infiltration (A) and characteristics of infiltrating cells (orginal magnification × 400) (B) in orbital tissues by immunohistochemistry in relation to the type of treatment. There was an absence of CD20+ cells with rituximab treatment compared with marked infiltration with intravenous steroid treatment. There were focal CD3+ infiltrates with rituximab treatment compared with marked expression with intravenous steroid treatment. There was evident CD68+ cell infiltration with rituximab treatment compared with focal infiltration with intravenous steroid treatment and no treatment. There was markedly increased CD163+ cell infiltration with rituximab treatment compared with focal infiltration with intravenous steroid treatment and no treatment.
Two women aged 43 and 67 years with primary myxedema and a 50-year-old woman with previous Graves hyperthyroidism treated with iodine 131 who were euthyroid while receiving levothyroxine and had active, moderate to severe GO with clinical activity scores (CASs) of 5/10, 6/10 (Figure 1A and B), and 6/7, respectively,4 were treated with rituximab. Infusion with 100 mg of rituximab was stopped at 60 minutes in 2 patients who had an infusion-related reaction with rapidly progressive, transient edema of soft orbital tissues and decrease of vision, and the patients were treated intravenously with 100 mg of hydrocortisone sodium succinate.
The first patient had edema and chemosis more pronounced in the left eye, with stretching of the optic nerve on orbital computed tomography due to marked periorbital tissue swelling (Figure 1B). Visual acuity returned to normal (10/10), and significant decreases of edema and inflammation (CAS decreased from 5 to 3) and proptosis in both eyes (decreasing from 24.5 to 23 mm OD and from 31 to 28 mm OS) were observed the next day. A week later, the disease was inactive (CAS of 2) (Figure 1A and B). The second patient had marked orbital edema (Figure 1B) and visual loss (counting fingers) in the more severely affected eye (the left eye). Orbital computed tomography showed only swelling of the retro-ocular tissue. Visual acuity improved in 60 minutes; 3 hours later, visual acuity was 10/10. A week later, inflammation improved bilaterally (CAS decreased from 6 to 3) (Figure 1A) and proptosis decreased (decreasing from 27.5 to 26 mm OD and from 29.5 to 27 mm OS) (Figure 1B). The third patient had no infusion-related effect, and the GO became inactive at 8 weeks (CAS decreased from 6 to 3). No disease relapse was observed in the patients at 32, 55, and 86 weeks of follow-up, respectively. Sixty minutes after treatment with 100 mg of rituximab, we recorded depletion of peripheral CD20+ and CD19+ cells (Figure 1C), similar to what is observed after receiving a standard rituximab dose. Immunohistochemistry (Figure 2B) in steroid-treated and untreated patients has shown CD20+ or CD3+ orbital infiltrates of variable degree but complete depletion of CD20+ cells and near complete depletion of CD3+ lymphocytes after receiving a low dose of rituximab. Of note, after rituximab treatment, there was significant infiltration of CD68+ macrophages, no CD1a+ dendritic cells, and good expression of CD163, a marker of type 2 macrophages. Control patients had only focal CD68+ and CD163+ cell infiltration.
We report, for the first time to our knowledge, that low-dose rituximab (100 mg) causes effective peripheral B-cell depletion and induces long-term remission of GO without further therapy. No data on the time for depletion after rituximab infusion have been previously reported in the literature. This observation was made after discontinuing rituximab treatment in 2 patients because of an important infusion-related reaction. Anaphylatoxins and cytokines might presumably be at the basis of the observed edema after rituximab treatment. Our data suggest that C3a and C5a anaphylatoxins and other inflammatory cytokines may have recruited CD68+CD163+CD1a− macrophages in orbital tissue observed at the time of surgical decompression. Interestingly, CD163 is a marker of type 2 macrophages, which are most active at driving phagocytosis.5 In contrast, type 1 macrophages are proinflammatory and involved in antigen presentation. Until now, a role for macrophages has not been described in the disease.
Rituximab treatment of GO may induce a clinical response that can vary from patient to patient, occur at a very early stage of disease activity, and persist long term.1 The small number of patients in this study suggests the need for caution in drawing more general conclusions from our observations: should these findings be confirmed, we would envisage a new treatment option with low-dose rituximab, with fewer adverse effects and more cost-effectiveness.
Correspondence: Dr Salvi, Endocrine Unit, Department of Medical Sciences (Padiglione Granelli), Fondazione Cà Granda, IRCCS, Via Sforza, 35, 20122, Milan, Italy (firstname.lastname@example.org).
Financial Disclosure: None reported.
Funding/Support: This work was supported in part by Ministero dell’Universita e della Ricerca Scientifica e Tecnologica, Rome, Italy, and Fondazione Cà Granda, IRCCS, Milan, Italy.
Thank you for submitting a comment on this article. It will be reviewed by JAMA Ophthalmology editors. You will be notified when your comment has been published. Comments should not exceed 500 words of text and 10 references.
Do not submit personal medical questions or information that could identify a specific patient, questions about a particular case, or general inquiries to an author. Only content that has not been published, posted, or submitted elsewhere should be submitted. By submitting this Comment, you and any coauthors transfer copyright to the journal if your Comment is posted.
* = Required Field
Disclosure of Any Conflicts of Interest*
Indicate all relevant conflicts of interest of each author below, including all relevant financial interests, activities, and relationships within the past 3 years including, but not limited to, employment, affiliation, grants or funding, consultancies, honoraria or payment, speakers’ bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. If all authors have none, check "No potential conflicts or relevant financial interests" in the box below. Please also indicate any funding received in support of this work. The information will be posted with your response.
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 11
Customize your page view by dragging & repositioning the boxes below.
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.